Understanding FDA's detention policy for imported kratom dietary supplements and bulk dietary ingredients.
Import Alert 54-15 is FDA guidance instructing field personnel how to handle certain imported dietary supplements and bulk dietary ingredients that are or contain Mitragyna speciosa (kratom). The alert authorizes detention without physical examination (DWPE) for products from firms on its Red List and provides instructions for handling similar products from firms not yet listed.
The alert is issued under section 801(a)(3) of the Federal Food, Drug, and Cosmetic Act, which allows FDA to detain imported products that appear to be adulterated or misbranded.
Most people — including lawmakers — have never read the alert. This page provides a plain-English guide to help you understand what it says, how it works, and why it matters for the shipping records in our investigation.
Instead of relying on summaries, read the agency's guidance yourself.
Detention Without Physical Examination of Certain Dietary Supplements and Bulk Dietary Ingredients That Are or Contain Mitragyna speciosa (Kratom)
Reading the primary source builds credibility and ensures you understand the alert's actual provisions, not just interpretations.
DWPE is a procedural tool described in the alert. The following flowchart illustrates how the process works for kratom imports.
DWPE is a procedural mechanism, not a final determination. Importers may submit evidence to demonstrate that their product complies with FDA requirements. The alert provides specific instructions for how FDA personnel should handle these submissions.
Key distinction: Products from Red List firms are subject to DWPE. Products from firms not on the Red List may be referred for Center Review. The public shipping records analyzed in our investigation do not reveal which firms are on the Red List or whether any specific shipment was subject to DWPE.
The alert specifically discusses the following product forms:
FDA specifically lists these product forms in the alert because they represent the types of products that have been associated with dietary supplement marketing. The alert notes that these products may be adulterated under the Federal Food, Drug, and Cosmetic Act because they contain a new dietary ingredient for which there is inadequate information to provide reasonable assurance that it does not present a significant or unreasonable risk.
The alert also references FDA's previous warnings and public health notifications regarding kratom.
Our investigation analyzed 500 public shipping records, identifying 367 unique kratom shipments representing 11,390 metric tons.
Shipping records show:
Shipping records do not tell us:
Bottom line: Shipping records reveal the scale and patterns of kratom imports. They do not reveal how FDA evaluated any specific shipment or whether Import Alert 54-15 was applied.
Some shipping records in this investigation include phrases such as "not for human consumption" or "external use."
Public shipping records alone do not establish why those phrases were used or how FDA evaluated any specific shipment. FDA may also consider labeling, marketing, websites, product form, and other evidence of intended use when determining whether a product falls within the scope of Import Alert 54-15.
A bill-of-lading phrase such as "not for human consumption" does not, by itself, establish how FDA classified the article or whether the agency had authority to examine, detain, or refuse it. FDA may consider the totality of evidence regarding intended use.
The presence of these phrases in shipping records raises questions about documentation practices. But those questions cannot be answered by the shipping records alone. They require access to customs entry documents and FDA records.
The shipping records and Import Alert 54-15 together raise several questions that policymakers may wish to explore.
Were any of the 367 identified shipments reviewed by FDA? If so, what was the outcome?
For firms not on the Red List, were any shipments referred for Center Review Detention?
Were any of these shipments detained under DWPE or through Center Review?
Did FDA determine that any of these products were dietary supplements or bulk dietary ingredients?
Were any shipments admitted into the United States after review? On what basis?
What intended-use evidence, labeling, or marketing materials accompanied the customs entries?
These questions cannot be answered by bills of lading alone. They require access to customs entry documents, FDA records, and potentially court records.
This page provides a plain-English summary of Import Alert 54-15. But the most persuasive analysis is reading the original document yourself.
Detention Without Physical Examination of Certain Dietary Supplements and Bulk Dietary Ingredients That Are or Contain Mitragyna speciosa (Kratom)
